WELCOME TO THE MYOSITIS COMMUNITY: This Patient-To-Patient Community is for discussions relating to Myositis which is an inflammation of skeletal muscles, which are also called the voluntary muscles. These are the muscles you consciously control that help you move your body. An injury, infection or autoimmune disease can cause myositis.
For support and advice from others,
visit our Myositis
Community
Myositis is the
chronic inflammation of muscle tissue. The
inflammatory myopathies are a group of diseases that involve myositis, accompanied
by muscle weakness. The primary types of chronic myositis are polymyositis, dermatomyositis,
and inclusion body myositis.
What
is Inclusion Body Myositis?
Inclusion body myositis (IBM) is one
of a group of muscle diseases known as the inflammatory myopathies, which are
characterized by chronic, progressive muscle inflammation accompanied by muscle
weakness. The onset of muscle weakness in IBM is generally gradual (over
months or years) and affects both proximal (close to the trunk of the body) and
distal (further away from the trunk) muscles. Muscle weakness may affect
only one side of the body. Falling and tripping are usually the first
noticeable symptoms of IBM. For some individuals, the disorder begins
with weakness in the wrists and fingers that causes difficulty with pinching,
buttoning, and gripping objects. There may be weakness of the wrist and
finger muscles and atrophy (thinning or loss of muscle bulk) of the forearm
muscles and quadricep muscles in the legs. Difficulty swallowing occurs
in approximately half of IBM cases. Symptoms of the disease usually begin
after the age of 50, although the disease can occur earlier. IBM occurs
more frequently in men than in women.
Is
there any treatment?
There is no cure for IBM, nor is
there a standard course of treatment. The disease is generally
unresponsive to corticosteroids and immunosuppressive drugs. Some
evidence suggests that intravenous immunoglobulin may have a slight, but
short-lasting, beneficial effect in a small number of cases. Physical
therapy may be helpful in maintaining mobility. Other therapy is
symptomatic and supportive.
What
is the prognosis?
IBM is generally resistant to all
therapies and its rate of progression appears to be unaffected by currently
available treatments.
What
research is being done?
The National Institute of
Neurological Disorders and Stroke (NINDS), National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS), National Institute of Environmental
Health Sciences (NIEHS) and other institutes of the National Institutes of
Health (NIH) conduct research relating to IBM in laboratories at the NIH and
support additional research through grants to major medical institutions across
the country. Currently funded research is exploring patterns of gene
expression among the inflammatory myopathies, the role of viral infection as a
precursor to the disorders, and the safety and efficacy of various treatment
regimens.
Source: Information provided courtesy of the National Institute of Neurological Disorders and
Stroke (NINDS), a division of the National
Institutes of Health (NIH).
NINDS health-related material is
provided for information purposes only and does not necessarily represent
endorsement by or an official position of the National Institute of
Neurological Disorders and Stroke or any other Federal agency. Advice on the
treatment or care of an individual patient should be obtained through
consultation with a physician who has examined that patient or is familiar with
that patient's medical history.
o Myositis
o
Polymyositis
o Dermatomyositis